| Meghann Kellie Vanslager, DPT | |
|
650 Lake Rd, Atwood, KS 67730-1535 | |
| (785) 626-9015 | |
| Not Available |
| Full Name | Meghann Kellie Vanslager |
|---|---|
| Gender | Female |
| Speciality | Physical Therapist - Geriatrics |
| Location | 650 Lake Rd, Atwood, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811220841 | NPI | - | NPPES |
| 11-05290 | Other | KS | KANSAS BOARD OF HEALING ARTS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2251G0304X | Physical Therapist - Geriatrics | 11-05290 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Meghann Kellie Vanslager, DPT 785 W 7th St, Colby, KS 67701-1902 Ph: (248) 895-5434 | Meghann Kellie Vanslager, DPT 650 Lake Rd, Atwood, KS 67730-1535 Ph: (785) 626-9015 |
News Archive
DePuy Synthes*, in collaboration with LifeNet Health®, launches ViviGen Formable™ Cellular Bone Matrix**, a second generation cellular allograft used to assist in the formation of bone during spinal fusion surgery. ViviGen Formable augments the DePuy Synthes biomaterials portfolio and joins the first generation, ViviGen® Cellular Bone Matrix, which launched in late 2014. With both ViviGen and ViviGen Formable, surgeons may now choose a preferred handling option based on the needs of each surgical case.
Researchers from the U.S. recently reported a multimodal "SHIELD: Target, Test, and Tell" program that helped mitigate the transmission of SARS-CoV-2 at a large public university. The program also prevented community transmission and helped the continuation of in-person classes during the pandemic. This study is available on the medRxiv* preprint server.
The Global Health Innovative Technology Fund, which in the last two years has invested US$43 million to develop innovative tools for fighting diseases worldwide, today announced it is investing $10.7 million at multiple points in the product development pipeline to seek new interventions for malaria, tuberculosis (TB), leishmaniasis and dengue.
Ruth Rose-Jacobs, ScD, associate professor of pediatrics at Boston University School of Medicine (BUSM) and a research scientist at Boston Medical Center (BMC), has received funding for a two-year study to examine the association between the presence of young children with special healthcare needs in households and food insecurity.
The antidiabetes drug rosiglitazone may have the potential to protect kidney function in patients with a condition called focal segmental glomerulosclerosis (FSGS), according to a study appearing in the January 2009 issue of the Clinical Journal of the American Society Nephrology (CJASN).
› Verified 3 days ago